DA-9501 (Dexmedetomidine) for Sedation During Surgery

Phase 3, randomised, double-blind trial of dexmedetomidine in Procedural sedation (PS) (5 arms), sponsored by Pfizer. Primary endpoint: Percentage of Patients Who Did Not Require Rescue Administration of Propofol to Achieve and Maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 During the Study Drug Administration. Started Jun 2011; status: completed.